Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging

ダウンロード数 : ? 件

この文献の参照には次のURLをご利用ください : https://ir.lib.shimane-u.ac.jp/53289

言語	英語
著者	津端由佳里 Hayashi Mitsuhiro Division of Molecular Pharmacology, National Cancer Center Research Institute, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Division of Clinical Pharmacology and Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan 谷野良輔 Aikawa Hiroaki Division of Clinical Pharmacology and Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Ohuchi Mayu Division of Molecular Pharmacology, National Cancer Center Research Institute, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Tamura Kenji Department of Breast and Medical Oncology, National Cancer Center Hospital, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Fujiwara Yasuhiro Department of Breast and Medical Oncology, National Cancer Center Hospital, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan 礒部威 Hamada Akinobu Division of Molecular Pharmacology, National Cancer Center Research Institute, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Division of Clinical Pharmacology and Translational Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
掲載誌名	SCIENTIFIC REPORTS
巻	7
ISSN	2045-2322
発行日	2017-10-3
DOI	10.1038/s41598-017-13025-8
PubMed ID	28974758
出版者	NATURE PUBLISHING GROUP
資料タイプ	学術雑誌論文
部局	医学部
備考	We thank all the people related to this study including patient and family. We also thank N. Ohtsuka, S. Ryu, T. Yoshino, Y. Murai, M. Mizui, M. Nishidate, and R. Matsukane for their help. This work was supported by grants from the Accelerating Regulatory Science Initiative, Ministry of Health, Labour and Welfare, Japan (Y.F.), the National Cancer Center Development Fund (26-A-20, A.H.), and in part the Project for Cancer Research And Therapeutic Evolution, Japan Agency for Medical Research and Development (16cm0106223h0001, M.H.).